Business Insider

Osteros Biomedica Presents Results of a Phase 1 Study of MBC-11, a Bone-Targeting Conjugate in Cancer Patients with Bone Metastases at ASCO Annual Meeting 2017

Osteros Biomedica announces the completion of Phase 1 clinical trial of its drug МВС-11 intended to treat patients with bone metastases and their associated clinical consequences. The results will be ...
ascopubs.org

Phase 1 study of the bone-targeting cytotoxic conjugate, etidronate-cytosine arabinoside (MBC-11), in cancer patients with bone metastases.

SWI/SNF complex subunit aberrations in diverse cancers: Next-generation sequencing of 539 patients. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include ...
FierceBiotech

Maxwell Biotech Venture Fund Invests in POC Clinical Program of a New Anti-Tumor Drug Candidate MBC-11 Targeting Metastatic Bone Disease

Maxwell Biotech Venture Fund Invests in POC Clinical Program of a New Anti-Tumor Drug Candidate MBC-11 Targeting Metastatic Bone Disease In early September the investment committee of Maxwell Biotech ...